ProQR Therapeutics(NASDAQ) PRQR

Market Cap$285.84M

Since IPO (2014)-86%

5 Year-70%

1 Year-13%

1 Month+5%

Premium Feature

Moneyball Superscore

50/100

$2.04

-1.45%

-0.03Today

ProQR Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 2.07	2026-09-04

ProQR Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.61%	USD 2.29	2026-08-28
1 month	+5.08%	USD 1.97	2026-08-05
3 month	+38%	USD 1.50	2026-06-05
Year to date	+2.48%	USD 2.02	2025-12-31
1 year	-13.39%	USD 2.39	2025-09-04
3 year	+29.37%	USD 1.60	2023-09-05
5 year	-70.04%	USD 6.91	2021-09-03
Since inception	-85.95%	USD 14.73	2014-09-18

ProQR Therapeutics Financials at a Glance

Market Cap

$285.84M

Revenue (TTM)

€18.57M

Net Income (TTM)

-€42.40M

EPS (TTM)

-$0.46

P/E Ratio

-4.46

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$2.04

Volume

52,855.476

Open

$2.07

Price

$2.04

Volume

52,855.476

Open

$2.07

Previous Close

$2.07

Daily Range

$2.02 - $2.11

52-Week Range

$1.33 - $3.10

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$2.04

Volume

52,855.476

Open

$2.07

Previous Close

$2.07

Daily Range

$2.02 - $2.11

52-Week Range

$1.33 - $3.10

Estimated Earnings Date

Nov 5, 2026

PRQR News

optometrist covering her patient’s eyes with an occluder during an eye exam

Page 1

PRQR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-based therapies for genetic disorders. The company is advancing its pipeline with two key drug candidates in late-stage clinical trials, while also innovating through its proprietary Axiomer RNA base-editing platform.

Products and Services

Sepofarsen: Targeting Leber Congenital Amaurosis 10 in Phase II/III trials
Ultevursen: Evaluating treatment for USH2A-mediated retinitis pigmentosa
Axiomer platform: Developing RNA base-editing technology for genetic conditions

Growth Outlook

Strong pipeline with two candidates in advanced clinical trials
Strategic partnerships with leading institutions enhance research capabilities
Significant cash reserves support ongoing development and operations

Financial Highlights

Recent quarterly revenue of €8.9 million shows growth potential
Cash and cash equivalents of €117 million provide financial stability
Operating expenses reflect ongoing investment in R&D for future growth

ProQR Therapeutics N.V. is positioned in the biotechnology sector, focusing on innovative solutions for genetic disorders. The company's commitment to research and development is evident in its advanced clinical trials and strategic collaborations with renowned institutions. With a robust cash position, ProQR is well-equipped to navigate the complexities of drug development while pursuing its mission to address unmet medical needs.

AI Generated • Aug 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

186.6

CEO

Daniel Anton de Boer

Website

www.proqr-tx.com

Headquarters

Leiden, ZH 2333 Ck, NL

PRQR Financials

Key Financial Metrics (TTM)

Gross Margin

92.33%

Operating Margin

-232.71%

Net Income Margin

-228.29%

Return on Equity

-68.44%

Return on Capital

-56.65%

Return on Assets

-31.76%

Earnings Yield

-22.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$285.84M

Shares Outstanding

138.09M

Volume

52.86K

Avg. Volume

1.09M

Financials (TTM)

Gross Profit

€17.15M

Operating Income

-€43.22M

EBITDA

-€37.69M

Operating Cash Flow

-€49.14M

Capital Expenditure

-€1.15M

Free Cash Flow

-€50.29M

Cash & ST Invst.

€117.08M

Total Debt

€13.19M

ProQR Therapeutics Performance Analysis

ProQR Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 3,777,202	136.0%
2023	2023-12-31	EUR 7,042,387	86.4%
2024	2024-12-31	EUR 20,449,364	190.4%
2025	2025-12-31	EUR 17,951,161	-12.2%

ProQR Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-23.6%
Q4	2025-12-31	60.8%
Q1	2026-03-31	-55.9%
Q2	2026-06-30	330.9%

ProQR Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -0.95	-16.7%
2023	2023-12-31	EUR -0.38	-60.3%
2024	2024-12-31	EUR -0.35	-7.1%
2025	2025-12-31	EUR -0.45	29.6%

ProQR Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	16.7%
Q4	2025-12-31	14.9%
Q1	2026-03-31	-52.8%
Q2	2026-06-30	37.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€8.90M

+133.3%

Gross Profit

€8.19M

+114.4%

Gross Margin

91.93%

N/A

Market Cap

$285.84M

N/A

Market Cap/Employee

$1.72M

N/A

Employees

166

N/A

Net Income

-€8.87M

+27.1%

EBITDA

-€8.25M

+28.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€117.08M

-16.7%

Total Debt

€13.19M

-25.3%

Accounts Receivable

€1.86M

-34.7%

Inventory

€0.00

N/A

Long Term Debt

€8.69M

-29.4%

Short Term Debt

€4.50M

-15.8%

Return on Assets

-31.76%

N/A

Return on Invested Capital

-43.82%

N/A

Free Cash Flow

-€12.70M

-10.4%

Operating Cash Flow

-€12.40M

-8.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TRDAEntrada Therapeutics, Inc.

TRDAEntrada Therapeutics, Inc.$7.22+1.25%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$5.38-1.01%

ARCTArcturus Therapeutics Holdings Inc.

ARCTArcturus Therapeutics Holdings Inc.$15.05-4.87%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$3.12-3.56%

CAPRCapricor Therapeutics, Inc.

CAPRCapricor Therapeutics, Inc.$8.92-5.10%

IMMPImmutep Limited

IMMPImmutep Limited$0.36-1.26%

MREOMereo BioPharma Group plc

MREOMereo BioPharma Group plc$0.25+0.48%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$101.51+0.06%

WYHGWing Yip Food Group

WYHGWing Yip Food Group$5.42+0.33%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$43.61-0.06%

NOKNokia

NOKNokia$10.40+0.04%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$124.75+0.06%

RGTIRigetti Computing

RGTIRigetti Computing$16.73+0.10%

NVDANvidia

NVDANvidia$231.98+0.01%

Questions About PRQR

What is the current price of ProQR Therapeutics?

ProQR Therapeutics is trading at $2.04 per share.

What is the 52-week range for ProQR Therapeutics?

Over the past 52 weeks, ProQR Therapeutics has traded between $1.33 and $3.10.

How much debt does ProQR Therapeutics have?

As of the most recent reporting period, ProQR Therapeutics reported total debt of €15.08M.

How much cash does ProQR Therapeutics have on hand?

ProQR Therapeutics reported €133.91M in cash and cash equivalents in its most recent financial results.

What is ProQR Therapeutics’s dividend yield?

ProQR Therapeutics does not currently have a dividend yield.

ProQR Therapeutics(NASDAQ) PRQR

ProQR Therapeutics Financials at a Glance

PRQR News

Why Shares of ProQR Therapeutics Dropped on Wednesday

Why ProQR Therapeutics Stock Got Slammed Again Monday

Why ProQR Therapeutics Is Crashing Today

Here's Why ProQR Stock Surged on Thursday

An End to This Rare Syndrome Could Be an Opportunity for Investors

Why ProQR Therapeutics Stock Is Popping Today

Why ProQR Therapeutics N.V. Is Soaring Again Today

3 Biotech Stocks That Soared This Week: Are They Buys?

PRQR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ProQR Therapeutics

PRQR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ProQR Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PRQR

What is the current price of ProQR Therapeutics?

What is the 52-week range for ProQR Therapeutics?

How much debt does ProQR Therapeutics have?

How much cash does ProQR Therapeutics have on hand?

What is ProQR Therapeutics’s dividend yield?

Premium Investing Services